The Potential of T Cell Immunoglobulin and Mucin-Domain containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer

(E-pub Ahead of Print)

Author(s): Monireh Mohsenzadegan, Parizad Bavandpour, Mohammad Reza Nowroozi, Erfan Amini, Masoumeh Kourosh-Arami, Seyed Ali Momeni, Saied Bokaie, Laleh Sharifi*

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Become EABM
Become Reviewer
Call for Editor


Targeting inhibitory receptors on T cells in the tumor sites can promote effective anti-tumor immunity in bladder cancer. Unfortunately, the main dilemma is that a large number of patients remain refractory to CTLA-4, PD-1, and PD-L1 blockade therapies. T-cell immunoglobulin and mucin domain 3 (Tim-3) is an inhibitory receptor expressed on T cells and innate immune cells. Both in vivo and in vitro data from patients with advanced cancers support the role of Tim-3 inhibition in satisfactory anti-tumor immunity. In bladder cancer, the expression level of Tim-3 significantly increases with advanced pathological grade and T stage. Therefore, rationality implies that designing novel monoclonal antibodies reactive with Tim-3 alone or in combination with other checkpoint inhibitors may indicate a favorable response in bladder cancer. Here, we aimed to investigate the possibility of targeting Tim-3 as a novel anti-cancer treatment for bladder cancer.

Keywords: Bladder cancer, T-cell immunoglobulin and mucin domain 3 (TIM-3), checkpoint inhibitor, inhibitory receptor, immunotherapy, monoclonal antibodies, anti-cancer treatment.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1871530321666210310142141
Price: $95

Article Metrics

PDF: 78